Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

AVM receives FDA clearance to study AVM-0703 for COVID-19- and influenza-related ARDS

Sep. 17, 2020

First patient dosed in phase II study of GC-4419 for COVID-19

Sep. 17, 2020

Profiling of JAK inhibitors AZD-4604 and AZD-0449 in translational rodent model of asthma

Sep. 15, 2020

FDA approves Trelegy Ellipta for asthma

Sep. 14, 2020

Phase III trial of Fasenra in nasal polyposis meets coprimary endpoints

Sep. 14, 2020

QBW-251: a CFTR potentiator in phase II for the treatment of COPD

Sep. 14, 2020

Results from a phase IIa POC trial of the oral adenosine A1 receptor antagonist PBF-680

Sep. 9, 2020

First phase I data presented for the neutrophil elastase inhibitor BI-1323495

Sep. 9, 2020

New personalized cystic fibrosis treatment treats Class V mutations

Sep. 9, 2020

Palobiofarma reports promising phase II data on PBF-680 for asthma

Sep. 7, 2020

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...